Anti-LIPI/ CT17/ LPDL monoclonal antibody

Anti-LIPI/ CT17/ LPDL antibody for FACS & in-vivo assay

Target products collectionGo to LIPI/LIPI products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2549-Ab-1/ GM-Tg-hg-MP2549-Ab-2Anti-Human LIPI monoclonal antibodyHuman
GM-Tg-rg-MP2549-Ab-1/ GM-Tg-rg-MP2549-Ab-2Anti-Rat LIPI monoclonal antibodyRat
GM-Tg-mg-MP2549-Ab-1/ GM-Tg-mg-MP2549-Ab-2Anti-Mouse LIPI monoclonal antibodyMouse
GM-Tg-cynog-MP2549-Ab-1/ GM-Tg-cynog-MP2549-Ab-2Anti-Cynomolgus/ Rhesus macaque LIPI monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2549-Ab-1/ GM-Tg-felg-MP2549-Ab-2Anti-Feline LIPI monoclonal antibodyFeline
GM-Tg-cang-MP2549-Ab-1/ GM-Tg-cang-MP2549-Ab-2Anti-Canine LIPI monoclonal antibodyCanine
GM-Tg-bovg-MP2549-Ab-1/ GM-Tg-bovg-MP2549-Ab-2Anti-Bovine LIPI monoclonal antibodyBovine
GM-Tg-equg-MP2549-Ab-1/ GM-Tg-equg-MP2549-Ab-2Anti-Equine LIPI monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2549-Ab-1/ GM-Tg-hg-MP2549-Ab-2; GM-Tg-rg-MP2549-Ab-1/ GM-Tg-rg-MP2549-Ab-2;
GM-Tg-mg-MP2549-Ab-1/ GM-Tg-mg-MP2549-Ab-2; GM-Tg-cynog-MP2549-Ab-1/ GM-Tg-cynog-MP2549-Ab-2;
GM-Tg-felg-MP2549-Ab-1/ GM-Tg-felg-MP2549-Ab-2; GM-Tg-cang-MP2549-Ab-1/ GM-Tg-cang-MP2549-Ab-2;
GM-Tg-bovg-MP2549-Ab-1/ GM-Tg-bovg-MP2549-Ab-2; GM-Tg-equg-MP2549-Ab-1/ GM-Tg-equg-MP2549-Ab-2
Products NameAnti-LIPI monoclonal antibody
Formatmab
Target NameLIPI
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LIPI benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LIPI/ CT17/ LPDL VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2549
    Target NameLIPI
    Gene ID149998,320355,288322,694591,608069,101095845,617574,100068765
    Gene Symbol and SynonymsCT17,D930038D03Rik,LIPI,lpd1,LPDL,mPA-PLA1 beta,PLA1C,PRED5
    Uniprot AccessionQ6XZB0
    Uniprot Entry NameLIPI_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188992
    Target ClassificationN/A

    The target: LIPI, gene name: LIPI, also named as CT17, LPDL, PLA1C, PRED5, mPA-PLA1 beta. The protein encoded by this gene is a phospholipase that hydrolyzes phosphatidic acid to produce lysophosphatidic acid. Defects in this gene are a cause of susceptibility to familial hypertrigliceridemia. This gene is also expressed at high levels in Ewing family tumor cells. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.